Boston Scientific has gained European marketing approval for its Emerge PTCA dilatation catheter designed for treating coronary artery lesions.
The next-generation Emerge pre-dilatation balloon catheter features a 1.2 mm diameter balloon option which includes an ultra-low 0.017" tip profile and low crossing profiles designed to cross tight lesions. The catheter’s 1.2 mm balloon leverages a durable balloon material to offer burst pressure (18 ATM) for sizing flexibility.
Available in a wide array of balloon diameters, from 1.2mm up to 4mm, with balloon lengths ranging from 8mm up to 30mm, the Emerge platform provides a reduced, low-friction shaft profile which facilitates simultaneous use of two Monorail balloon catheters in a 6F guide catheter and two OTW balloon catheters in an 8F guide catheter.
Both the Monorail and OTW catheters are available with two shaft technologies, including Push technology (1.2mm and 1.5mm) which offers a single-segment inner shaft for pushability, while Workhorse technology (1.2mm to 4mm) includes a bi-segment inner shaft designed for deliverability.
Kevin Ballinger, Boston Scientific cardiovascular division president, said the Emerge catheter builds on the company’s expertise in developing such technology and its commitment to offering advanced devices to treat coronary artery disease.
"The innovative features and broad range of available options for the Emerge platform enables physicians to select the appropriate catheter based on clinical need, helping to improve outcomes for patients undergoing coronary interventions," Ballinger added.
Currently, the Emerge 1.2mm and 1.5mm PTCA dilatation catheters are under review by the US Food and Drug Administration. The company plans to launch the Emerge catheter in the US and additional international markets later this year.